Company Contents
Quick Facts & Snapshot
Summary
The global Angioplasty Devices market is in a sustained growth phase, driven by rising cardiovascular disease burden, minimally invasive preferences, and continuous stent and catheter innovation. Leading Angioplasty Devices market companies are consolidating share through premium drug-eluting technologies and service-led models. From US$ 14.10 Billion in 2025 to US$ 21.40 Billion by 2032, the market grows at a 6.20% CAGR.
Source: Secondary Information and ReportMines Research Team - 2026
Ranking Methodology
Rankings of Angioplasty Devices market companies are based on a composite score combining quantitative and qualitative inputs. Quantitatively, we assess 2025 angioplasty-related revenue, three-year segment growth, share in key regions, tender wins, and installed base across leading cath labs. Qualitative indicators include technology differentiation in stents and balloons, breadth of coronary and peripheral portfolios, integration of imaging and guidance, service coverage, and strength of long-term maintenance and training programs. Each factor is normalized on a 0-10 scale and weighted, with revenue and growth jointly contributing roughly 50% of the score, technology and portfolio 30%, and service plus strategic execution 20%. Inputs span company filings, regulatory databases, hospital procurement data, and structured interviews with clinicians and purchasers. The resulting ranking highlights not only current scale but also strategic positioning for future share gains.
Top 10 Companies in Angioplasty Devices
Source: Secondary Information and ReportMines Research Team - 2026
Detailed Company Profiles
Medtronic plc
Medtronic is a global cardiovascular leader offering a comprehensive portfolio of angioplasty devices, structural heart therapies, and cardiac rhythm management solutions.
Boston Scientific Corporation
Boston Scientific focuses on high-end interventional cardiology solutions, excelling in complex PCI, drug-eluting stents, and adjunctive angioplasty technologies worldwide.
Abbott Laboratories (Abbott Vascular)
Abbott Vascular leverages diagnostics and device integration to deliver angioplasty solutions spanning coronary stents, balloons, pressure wires, and imaging catheters.
Terumo Corporation
Terumo is a Japanese medtech company recognized for leadership in radial access and specialized interventional angioplasty tools used globally.
B. Braun Melsungen AG
B. Braun offers a broad vascular therapy portfolio, competing strongly in angioplasty balloons and accessories across Europe and selected global markets.
Cardinal Health, Inc.
Cardinal Health combines extensive distribution capabilities with a growing portfolio of branded and private-label angioplasty devices and accessories.
BIOTRONIK SE & Co. KG
BIOTRONIK is an innovation-driven European company with strong drug-eluting stent and peripheral angioplasty offerings, supported by robust clinical evidence.
Philips Image-Guided Therapy (Philips Healthcare)
Philips integrates imaging, navigation, and select angioplasty devices to create comprehensive image-guided therapy ecosystems for cath labs and hybrid ORs.
Merit Medical Systems, Inc.
Merit Medical specializes in interventional accessories and niche angioplasty balloons, enabling customized procedural solutions for cath labs.
Cook Medical LLC
Cook Medical delivers peripheral-focused angioplasty solutions, including balloons, stents, and access tools for vascular specialists worldwide.
SWOT Leaders
Medtronic plc
SWOT Snapshot
Broad angioplasty portfolio across coronary and peripheral, strong brand, deep hospital relationships, robust global service footprint.
High exposure to reimbursement pressure and tender-driven pricing, complex portfolio integration across acquired businesses.
Growing PCI procedure volumes in Asia Pacific, expansion of drug-coated balloons into new indications, emerging-market infrastructure upgrades.
Intensifying competition from value-based players, regulatory scrutiny on device safety, potential supply-chain disruptions for key components.
Boston Scientific Corporation
SWOT Snapshot
Strong innovation culture, leading position in complex PCI, rich DES pipeline supported by long-term clinical outcomes data.
High R&D spend pressures margins, concentrated reliance on premium coronary stents and adjacent high-end technologies.
Rising adoption of complex PCI, CTO procedures, and imaging-guided interventions in developed and emerging markets.
Competitive launches of next-generation DES and DCB platforms, healthcare cost-containment policies impacting premium pricing.
Abbott Laboratories (Abbott Vascular)
SWOT Snapshot
Integrated diagnostics and vascular portfolio, strong global footprint, trusted XIENCE DES brand with extensive real-world evidence.
Legacy perception issues from withdrawn scaffold technologies, complex organizational structure across diversified healthcare segments.
Expansion of physiology-guided PCI, cross-selling across diagnostics and devices, penetration in underdeveloped cath lab markets.
Intense pricing competition in DES, evolving regulatory requirements for next-generation scaffolds, macroeconomic headwinds affecting capital spending.
Angioplasty Devices Market Regional Competitive Landscape
North America remains the largest revenue contributor, with high PCI penetration, strong reimbursement, and rapid uptake of drug-eluting technologies. Medtronic, Boston Scientific, and Abbott dominate, supported by entrenched relationships with integrated delivery networks. Angioplasty Devices market companies increasingly differentiate through clinical evidence, decision-support integration, and outcomes-based contracting models with major health systems.
Europe shows a mature but innovation-sensitive market, with strict cost controls and centralized procurement. B. Braun, BIOTRONIK, and Terumo compete aggressively against US multinationals in public tenders. Growth stems from peripheral artery disease treatment and adoption of radial access, where Terumo holds a strong edge. Environmental and value-based procurement criteria increasingly shape device selection decisions.
Asia Pacific is the fastest-growing region, underpinned by rising cardiovascular disease prevalence, cath lab expansion, and growing middle-class access. Medtronic, Abbott, and Boston Scientific invest in localized manufacturing and training centers, while Terumo leverages its regional strength. Pricing sensitivity favors cost-competitive Angioplasty Devices market companies, including local Chinese and Indian manufacturers gaining share in value segments.
Latin America delivers mid-single-digit growth amid economic volatility and uneven reimbursement environments. Boston Scientific and Medtronic lead premium tiers, while B. Braun and Cardinal Health compete strongly in mid-range offerings. Infrastructure constraints and foreign-exchange risks challenge imports, favoring Angioplasty Devices market companies able to offer financing, inventory management, and hybrid pricing plus service packages.
The Middle East and Africa region remains relatively underpenetrated but strategically important, driven by expanding tertiary-care hubs and government investment in cardiac centers. Abbott, BIOTRONIK, and Medtronic are visible in flagship hospitals, often partnering on training. Market access depends on regulatory agility, distributor networks, and tailored portfolios addressing both premium and budget-constrained segments.
Emerging regional trends include consolidation of hospital groups, rise of cross-border care, and greater use of tele-mentoring for complex PCI cases. Angioplasty Devices market companies respond by building regional training academies, remote support platforms, and integrated imaging-plus-device offerings. Success increasingly hinges on blending localized service capabilities with globally validated technologies and evidence.
Angioplasty Devices Market Emerging Challengers & Disruptive Start-Ups
Emerging Challengers & Disruptive Start-Ups
Develops ultra-low-profile radial angioplasty balloons and access systems optimized for same-day discharge PCI workflows.
Working on nanocoated, ultra-thin strut stents designed to shorten dual antiplatelet therapy duration and reduce late thrombosis risk.
Provides AI-powered decision-support software that integrates with angioplasty devices to optimize lesion assessment and device sizing in real time.
Focuses on cost-effective bioresorbable scaffold platforms aimed at emerging markets, emphasizing local manufacturing and competitive pricing.
Develops sensor-embedded guidewires and balloons that provide continuous intravascular pressure and flow data during angioplasty procedures.
Regional challenger offering value-priced balloons and stents tailored to Latin American reimbursement levels and cath lab infrastructure.
Angioplasty Devices Market Future Outlook & Key Success Factors (2026-2032)
From 2025 to 2031, cumulative investments in metro expansions and station safety upgrades are projected to surpass significant amounts. The total market will scale from US$ 2.27 Billionin 2025 to US$ 3.38 Billion by 2031, reflecting a 6.90% CAGR. Winning Angioplasty Devices market companies will share several attributes. First, they will embed native IoT sensors, enabling predictive maintenance contracts that can double recurring revenue within five years. Second, modular design philosophies—interchangeable panels, plug-and-play controllers—will shorten installation windows and appeal to cost-sensitive public operators.
Localization strategies will also define competitive edges. Suppliers that establish regional assembly plants to meet content rules in India, Brazil, or the U.S. are likely to capture bonus points in tenders. Finally, sustainability credentials will move from optional to mandatory. Recyclable composite panels, energy-efficient brushless motors, and life-cycle carbon disclosures will become bid differentiators. In short, the coming decade rewards Angioplasty Devicesmarket companies that marry digital intelligence with manufacturing agility and regulatory foresight.
Frequently Asked Questions
Find answers to common questions about this company report.